Discontinuing cholinesterase inhibitor vs continued cholinesterase inhibitor
SAEs · people with dementia
Discontinuing cholinesterase inhibitor showed no clear difference in serious adverse events (SAEs) compared with continued cholinesterase inhibitor (low certainty).
1 finding from 1 review
- Withdrawal or continuation of cholinesterase inhibitors or memantine or both, in people with dementia 2021 · Cochrane Headline outcomes onlyOR 0.8 [0.46, 1.39]4 studies · 390 participantsLow